Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA focuses on developing innovative therapies and diagnostics for neurodegenerative diseases, leveraging proprietary technologies to target misfolded proteins. The company's pipeline, which includes promising candidates like ACI-7104.056 and ACI-24, has shown significant early results, such as a 20-fold increase in antibodies against pathogenic variants and stabilization of critical neurological markers, indicating strong therapeutic potential. The impending release of data on plaque removal for ACI-24 is anticipated to be a key catalyst, particularly for addressing high-risk patients, thereby enhancing the company's position in the Alzheimer's treatment landscape.

Bears say

AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, reflecting the substantial financial challenges the company is currently facing. Additionally, the company's net loss for the year 2025 reached CHF 70.4 million, with basic and diluted earnings per share (EPS) recorded at (0.70), indicating a negative return on investment for shareholders. The company also contends with inherent industry risks, including potential negative outcomes from clinical trials, regulatory uncertainties, and the complexities of price-sensitive commercial markets for its product candidates.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.